NICE changes its mind on Novartis’ progressive MS drug MayzentUK cost-effectiveness agency NICE has backed Novartis’ Mayzent for secondary progressive multiple sclerosis (SPMS), after turning it down Share XNICE changes its mind on Novartis’ progressive MS drug Mayzenthttps://pharmaphorum.com/news/nice-changes-its-mind-on-novartis-progressive-ms-drug-mayzent/
Axovant pushes on with Parkinson’s gene therapy, despite investor cynicismAxovant has said it plans to continue developing its Parkinson’s Disease gene therapy after reporting supportive data from Share XAxovant pushes on with Parkinson’s gene therapy, despite investor cynicismhttps://pharmaphorum.com/news/axovant-pushes-on-with-parkinsons-gene-therapy/
Israel’s NeuroHelp to trial AI device that predicts epileptic seizuresNeuroHelp, a spin-off from Israel’s Ben-Gurion University of the Negev, has developed what it claims to be the Share XIsrael’s NeuroHelp to trial AI device that predicts epileptic seizureshttps://pharmaphorum.com/news/israels-neurohelp-to-trial-ai-device-that-predicts-epileptic-seizures/
UK government invests £32m in health tech projectsThe UK government is to invest £32 million ($41.5 million) in six health technology projects aiming to transform Share XUK government invests £32m in health tech projectshttps://pharmaphorum.com/news/uk-government-invests-32m-in-health-tech-projects/
Mission successful for Novartis after FDA approves ofatumumab in MSIt’s mission accomplished for Novartis after the FDA approved ofatumumab for multiple sclerosis, completing a project where the Share XMission successful for Novartis after FDA approves ofatumumab in MShttps://pharmaphorum.com/news/mission-successful-for-novartis-after-fda-approves-ofatumumab-in-ms/
Roche takes on Alexion as FDA approves satralizumab in NMOSDThe FDA has approved Roche’s satralizumab for the rare autoimmune disorder Neuromyelitis Optica Spectrum Disorder (NMOSD), under the Share XRoche takes on Alexion as FDA approves satralizumab in NMOSDhttps://pharmaphorum.com/news/roche-takes-on-alexion-as-fda-approves-satralizumab-in-nmosd/
Bayer adds menopause drug to pipeline with KaNDy acquisitionBayer is to buy UK-based KaNDy Therapeutics in a deal worth more than $800 million, adding the biotech’s Share XBayer adds menopause drug to pipeline with KaNDy acquisitionhttps://pharmaphorum.com/news/bayer-adds-menopause-drug-to-pipeline-with-kandy-acquisition/
Roche takes on pricey rivals as FDA approves SMA drugRoche is hoping to undercut hugely expensive rivals after the FDA approved its oral spinal muscular atrophy (SMA) Share XRoche takes on pricey rivals as FDA approves SMA drughttps://pharmaphorum.com/news/roche-takes-on-pricey-rivals-as-fda-approves-sma-drug/
Biogen signs $2.1 billion Parkinson’s disease deal with DenaliBiogen has bought a licence to co-develop and co-market potential Parkinson’s disease drugs with US biotech Denali, in Share XBiogen signs $2.1 billion Parkinson’s disease deal with Denalihttps://pharmaphorum.com/news/biogen-signs-2-1-billion-parkinsons-disease-deal-with-denali/
